These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 16600214)

  • 1. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
    Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
    Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
    Giuliani N; Colla S; Morandi F; Rizzoli V
    Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.
    Hideshima T; Chauhan D; Schlossman R; Richardson P; Anderson KC
    Oncogene; 2001 Jul; 20(33):4519-27. PubMed ID: 11494147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
    Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI
    Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
    Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
    Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant B-lymphoid cells with bone lesions express receptor activator of nuclear factor-kappaB ligand and vascular endothelial growth factor to enhance osteoclastogenesis.
    Shibata H; Abe M; Hiura K; Wilde J; Moriyama K; Sano T; Kitazoe K; Hashimoto T; Ozaki S; Wakatsuki S; Kido S; Inoue D; Matsumoto T
    Clin Cancer Res; 2005 Sep; 11(17):6109-15. PubMed ID: 16144909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
    Hayashi T; Hideshima T; Nguyen AN; Munoz O; Podar K; Hamasaki M; Ishitsuka K; Yasui H; Richardson P; Chakravarty S; Murphy A; Chauhan D; Higgins LS; Anderson KC
    Clin Cancer Res; 2004 Nov; 10(22):7540-6. PubMed ID: 15569984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
    Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
    Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary adenylate cyclase-activating polypeptide is a potent inhibitor of the growth of light chain-secreting human multiple myeloma cells.
    Li M; Cortez S; Nakamachi T; Batuman V; Arimura A
    Cancer Res; 2006 Sep; 66(17):8796-803. PubMed ID: 16951196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction.
    Mbalaviele G; Anderson G; Jones A; De Ciechi P; Settle S; Mnich S; Thiede M; Abu-Amer Y; Portanova J; Monahan J
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1044-53. PubMed ID: 16501068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.
    Oba Y; Lee JW; Ehrlich LA; Chung HY; Jelinek DF; Callander NS; Horuk R; Choi SJ; Roodman GD
    Exp Hematol; 2005 Mar; 33(3):272-8. PubMed ID: 15730850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human microvascular endothelial cell activation by IL-1 and TNF-alpha stimulates the adhesion and transendothelial migration of circulating human CD14+ monocytes that develop with RANKL into functional osteoclasts.
    Kindle L; Rothe L; Kriss M; Osdoby P; Collin-Osdoby P
    J Bone Miner Res; 2006 Feb; 21(2):193-206. PubMed ID: 16418775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro.
    Balga R; Wetterwald A; Portenier J; Dolder S; Mueller C; Hofstetter W
    Bone; 2006 Aug; 39(2):325-35. PubMed ID: 16580896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
    Lin B; Podar K; Gupta D; Tai YT; Li S; Weller E; Hideshima T; Lentzsch S; Davies F; Li C; Weisberg E; Schlossman RL; Richardson PG; Griffin JD; Wood J; Munshi NC; Anderson KC
    Cancer Res; 2002 Sep; 62(17):5019-26. PubMed ID: 12208756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].
    Li J; Luo SK; Hong WD; Zhou ZH; Zou WY
    Ai Zheng; 2003 Apr; 22(4):346-9. PubMed ID: 12703985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms involved in the enhancement of osteoclast formation by enamel matrix derivative.
    Itoh N; Kasai H; Ariyoshi W; Harada E; Yokota M; Nishihara T
    J Periodontal Res; 2006 Aug; 41(4):273-9. PubMed ID: 16827720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional osteoclast-like transformation of cultured human myeloma cell lines.
    Calvani N; Cafforio P; Silvestris F; Dammacco F
    Br J Haematol; 2005 Sep; 130(6):926-38. PubMed ID: 16156862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on the pathogenesis of osteolysis in multiple myeloma patients.
    Giuliani N; Colla S; Rizzoli V
    Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RANK ligand expression in heat shock factor-2 deficient mouse bone marrow stromal/preosteoblast cells.
    Kajiya H; Ito M; Ohshima H; Kenmotsu S; Ries WL; Benjamin IJ; Reddy SV
    J Cell Biochem; 2006 Apr; 97(6):1362-9. PubMed ID: 16365894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
    Nefedova Y; Landowski TH; Dalton WS
    Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.